ReviewVaccine2011
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
Review in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial.The American journal of tropical medicine and hygiene · 2020Trial
- Dengue Vaccines.Current topics in microbiology and immunology · 2026Review
- Review
- Decoding Dengue: A Global Perspective, History, Role, and Challenges.Pathogens (Basel, Switzerland) · 2025Review
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference.NPJ vaccines · 2025Article
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
- Article
- Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development.Frontiers in immunology · 2024Article
- Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.The Journal of general virology · 2023Review
- Review
- Selection and Characterization of Single-Stranded DNA Aptamers of Diagnostic Potential against the Whole Zika Virus.Viruses · 2022Article
- Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice.Frontiers in tropical diseases · 2022Article
- Updates on Dengue Vaccine and Antiviral: Where Are We Heading?Molecules (Basel, Switzerland) · 2021Review
- Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?Frontiers in medical technology · 2021Review
- Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice.Molecular therapy. Methods & clinical development · 2020Article
- Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.Journal of virology · 2020Article
- Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein.Applied microbiology and biotechnology · 2020Article
- Efficient Delivery of Dengue Virus Subunit Vaccines to the Skin by Microprojection Arrays.Vaccines · 2019Article
- Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes.PLoS pathogens · 2019Article
- Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.PLoS neglected tropical diseases · 2018Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.